Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production by unknown
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The course and outcome of Friend virus complex (FV)l-induced erythroleukemia 
is  influenced  by several  mouse  genes  (1,  2).  Spontaneous  recovery from  leukemia 
occurs in  certain  strains  of mice  (3,  4)  and  appears  to be  a  complex phenomenon 
requiring the interaction of several mechanisms controlled by different genes (5, 6). 
For example, genes associated with the mouse major histocompatibility complex (H- 
2)  interact  in  a  complementary manner with  at  least  one non-H-2 gene  (Rfv-3)  to 
produce a  high  incidence of recovery from  leukemia  (7,  8).  In  the  absence  of the 
appropriate  high  recovery H-2  genotype,  the  Rfv-3 gene  influences  recovery from 
viremia in spite of progressive fatal leukemia (8). 
The present work is an investigation of the mechanism of action of the Rfv-3 gene. 
A.BY and A  mice have the Rfv-3  s/s genotype and do not recover from FV viremia, 
whereas  (B10.A  ×  A.BY)Fa and  (B10.A  ×  A)F1  mice  have  the  Rfv-3  r/s  genotype 
which is associated with recovery from FV viremia (8).  In previous experiments we 
observed that 30-90 d after FV inoculation, the leukemic spleen cells of these F1 mice 
were  no  longer susceptible  to  cytolysis by anti-FV  antibody  plus  complement  (9). 
Furthermore, these spleen cells were found to have lost 80% of their FV-induced cell- 
surface antigens (9). Our present data indicate that in addition to recovery from FV 
viremia  (8),  the  Rfv-3 gene also influences loss of FV-induced cell-surface antigens 
and generation of cytotoxic anti-leukemia cell antibody. Evidence is presented which 
indicates  that  anti-leukemia  cell  antibody  is  responsible  for  FV  antigen  loss  and 
recovery from FV viremia. 
Materials and Methods 
Mouse  Strains.  C57BL/10Sn (BI0),  B10.A, A.BY, and A/WySn (A)  mice were purchased 
from The Jackson Laboratory, Bar Harbor, Maine.  (B10.A ×  A)F1, (B10.A ×  A.BY)F1, and 
(B10.A ×  A)Ft  ×  A backcross mice were bred at the Rocky Mountain Laboratory, Hamilton, 
Mont. 
* Predoctoral fellow in Microbiology,  Montana State University, Bozeman, Montana. Supported by a 
grant from the Research Administration Office, Montana State University, Bozeman, Montana. 
1Abbreviations used in this paper." A, A/WySn; B10, C57BL/10Sn; CMC, cell-mediated cytotoxicity; F- 
MuLV, Friend murine leukemia helper virus; FFU, focus-forming  units; FV, Friend virus complex; MLV, 
Moloney leukemia virus; PFU, plaque-forming  units. 
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Virus.  The B-tropic strain of FV was used (10), and virus stocks were prepared as previously 
described  (4). 1,500 spleen  focus-forming  units  (FFU)  were injected intravenously (i.v.) to 
induce leukemia. 
Virus Assay.  The S+L  -  assay of Bassinet al.  (11) for the Friend murine leukemia  helper 
virus (F-MuLV) was previously described  (12). Results were expressed as plaque-forming units 
(PFU). 
Cytotoxicity Assay.  A  two-step  antibody plus rabbit  complement 51Or-release cytotoxicity 
assay was employed (9). Sera were tested for anti-FV cytotoxic activity using a (B10.A X A)FI 
FV-induced leukemia cell line, AA41, as target cells (13). The titer was defined as the last 
dilution which gave 10% or greater specific cytotoxicity. 
Immunofluorcscence.  Virus-specific membrane and intracellular immunofluorescence was stud- 
ied  using  fluorescein-conjugated  goat  anti-Moloney leukemia  virus  (anti-MLV)  from  the 
National Cancer Institute Viral Oncology Program as previously described  (9). 
Immunization.  Mice which had recovered from leukemia were inoculated two to five times 
i.v., every 2-4 wk with 2.5 ×  10  ~  syngeneic high antigen 8-9 d leukemic spleen cells to produce 
hyperimmune mice, which then had high titers of circulating anti-FV cytotoxic antibodies. 
Results 
Recove(y  from F-MuL V Viremia, Loss of FV Antigen, and Presence of Anti-FV Antibody Are 
Associated in (BIO.A  ×  A)F1 Mice.  35-37 d after inoculation of (B10.A ×  A)Fx mice 
with FV, plasm~i  F-MuLV was high (>10  a PFU/ml)  in only 3 of 39 mice (Table I) 
and leukemic spleen cells from only 1 mouse had high levels of membrane immuno- 
fluorescence (>50% positive) (Table I). In addition, most mice (34/43) had cytotoxic 
anti-FV leukemia cell antibodies, which were capable of lysing early (8-9 d), but not 
late (30-90 d), leukemic spleen cells (Table I). Similar results for viremia, loss of FV 
antigen, and presence of anti-FV antibody were seen with  (B10.A  ×  A.BY)F1 mice 
(data riot shown). 
Viremia, FV Antigen  Retention, and Absence of Anti-FV Antibody in A.BY and A/WySn 
Mice.  In contrast to the Fa mice, A.BY and A mice did not recover from viremia. 35- 
37 d  after FV inoculation,  18 of 21  mice still had >10  a PFU/ml  plasma  F-MuLV 
(Table I). In addition, most A.BY and A mice (19/21) did not exhibit a  loss of FV- 
induced cell-surface antigens in late stages of the leukemia  (Table I). Finally, most 
A.BY and A mice failed to develop demonstrable cytotoxic anti-FV antibodies during 
late stages  of the disease  (only 2 of 23  had  titers _>4) (Table I). The difference in 
recovery from viremia between (B10.A  ×  A)Fx and A  strains was previously deter- 
mined to be influenced by a non-H-2 gene, Rfv-3 (8). To determine whether the loss 
of FV-induced cell-surface antigens and production of cytotoxic anti-FV antibodies 
were under similar genetic control, individual  (B10.A  X  A)Fa  ×  A  backeross mice 
were studied. 
Comparison of F-MuL V  Viremia, FV-Induced Cell-Surface Antigens, and Anti-FV Antibody 
in  (BIO.A  ×  A)Fx  X  A  Backcross Mice.  Plasma  and  spleens were collected from 
backcross mice 35-37 days after FV inoculation. Plasma F-MuLV levels in backcross 
mice segregated nearly equally between high (> 103 PFU/ml) (24 mice) and low (< 10  a 
PFU/ml)  (27  mice)  (Table I).  A  similar  segregation  was  seen  for FV  cell-surface 
antigen loss;  27 mice had low nun~bers of cells (<50%) with FV-induced cell-surface 
antigens and 24 mice had high (>50% positive) levels of membrane immunofluores- 
eence (Table I). Fig.  1 (left column) shows the distribution of membrane immunoflu- 
orescence values for the backcross mice and demonstrates the existence of two groups 
corresponding to the Fa and A  parents. Cytotoxic anti-FV antibody also segregated 12  IDENTIFICATION OF Rfv-3 
TABLE I 
Comparison of F-MuL V Viremia, FV-Induced Cell-Surface Antigens, and Anti-FV Antibody in 
(BIO.A × A)F1, A.BY, A, and (BIO.A × A)F1 × A Mice* 
Rfv-3 geno-  F-MuLV  FV-induced cell-  Anti-FV anti-  Mouse strain  type  viremia~:  surface antigens§  body [[ 
(B10.A X A)F1  r/s 
A.BY and A¶  s/s 
(B10.A X A)F1 ×  A  50% s/s 
50% r/s 
(%)  (%)  (%) 
3/39 (8)  1/39 (3)  34/43 (79) 
18/21 (86)  19/21 (90)  2/23 (9) 
24/51 (47)  24/51 (47)  28/50 (57) 
*  35-37 d after infection with FV, mice were bled and the spleens were harvested. 
:]: F-MuLV viremia was assayed by the S+L  - assay. Values shown are number of mice with >103 PFU/ml 
plasma per total mice tested. 
§ Values shown are number of mice with >50% cells positive for membrane immunofluorescence  with goat 
anti-MLV serum/total  mice tested. 
[1 Values shown are number of mice with an anti-FV antibody titer of-->4  in the antibody plus complement 
cytotoxicity assay per total mice tested. 
¶ 14 A.BY and 9 A mice were used. 
nearly equally  between  high  and  low  levels.  22  mice  had  titers  of <4,  and  28  had 
titers -->4 (Table I). Therefore, recovery from viremia, loss of FV-induced cell-surface 
antigens,  and  generation  of cytotoxic anti-FV  antibody  were each  influenced  by a 
single genetic locus. 
By comparing these three parameters  in individual  backcross mice, we determined 
that all three were influenced by the same gene, Rfv-3. A strong association was found 
between recovery from viremia, loss of FV-induced cell-surface antigens, and presence 
of anti-FV antibody (Table II). Mice which had high plasma F-MuLV (>103 PFU/ 
ml)  were usually found to have high virus-specific immunofluorescence.  Mice which 
had  low  plasma  F-MuLV  (<103  PFU/ml)  were  typically found to have  low  virus- 
specific membrane immunofluorescence. Similarly, the presence of cytotoxic anti-FV 
antibodies  in plasma  from leukemic mice was associated  with  low plasma  F-MuLV 
levels  and  with  low  incidences  of virus-specific  immunofluorescent-positive  cells  in 
spleens.  Low cytotoxic anti-FV  antibody  titers  in  plasma  from  leukemic  backcross 
mice were associated with high plasma F-MuLV levels and with high percent  virus- 
specific membrane  fluorescence on spleen  cells. Thus, approximately one-half of the 
backcross mice were similar to the (B10.A  ×  A)F1 parents and appeared to have the 
dominant  B10.A allele of the Rfv-3 gene associated with recovery from viremia,  loss 
of FV-induced  cell-surface  antigens,  and  generation  of cytotoxic anti-FV  antibody. 
The other half of the backcross mice were similar to the A strain and appeared to lack 
the B10.A allele of Rfv-3. 
Kinetics  of  anti-FV  Antibody  Development  Vs.  Loss  of  FV-Specific  Cell-Surface 
Antigens.  The simplest explanation for the association of a single gene with clearance 
of viremia, decreased antigen expression, and appearance of antibody would be that 
one gene controls a  single parameter which affects all  three  variables.  For example, 
Rfv-3 may regulate  the  production  of anti-FV  antibodies  which  might  then  act  to 
clear  viremia  and  decrease  FV  antigen  expression  on  the  surface  of spleen  cells.  If 
anti-FV antibody does decrease FV-induced cell-surface antigens, it should be possible 
to detect a  rise in anti-FV antibody titer concurrently with or slightly before the time 
at which cell-surface antigens decrease. This was observed when (B 10.A  ×  A)F1 mice DON  DOIG AND BRUCE  CHESEBRO 
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FIG.  1.  Percentage of leukemic spleen cells from (BI0.A ×  A)F1 X A backcross, (BI0.A ×  A)F1, 
(BI0.A  ×  A.BY)F1, A.BY and A mice with virus-specific membrane  immunofluorescence 35-37 
days following FV inoculation. The two strains of late F~ mice were pooled, as were the A and A.BY 
mice, because they were indistinguishable with respect to membrane immunofluorescence (9). The 
cells were  reacted with fluorescein-conjugated goat anti-MLV serum.  Each  point represents one 
mouse spleen. 
13 
were examined for membrane immunofluorescence and anti-FV antibody at various 
times after FV inoculation.  The percent  of spleen cells with FV-induced cell-surface 
antigens  increased rapidly to a  plateau  (60-70% positive in the fluorescent antibody 
assay)  which  persisted  from  about  day  8  to  around  day  20  after  FV  injection. 
Thereafter,  the  percentage  of positive  cells  decreased  to levels characteristic  of late 
spleens  (Fig.  2).  Starting  on  about  day  21,  anti-FV  antibody  was  first  detected  in 
plasma  of leukemic  mice.  Some  mice with  demonstrable  antibody still  had  a  high 
percent  of cells  with  FV  cell  membrane  antigen.  However,  the  close  association 
between  antibody production and antigen  loss supports the hypothesis that anti-FV 
antibody is involved in the induction of antigen loss. 
Loss of FV Antigens after  Passive Antibody  Administration.  In an  attempt  to directly 
demonstrate  that  anti-FV  antibodies  were capable of inducing FV antigen  loss, we 
passively  administered  anti-FV  antibody  to  mice.  25  million  viable  early  (8-9  d) 
(B 10.A ×  A)FI spleen cells were given i.v. to lethally irradiated  (900 rads) nonimmune 
(B10.A  ×  A.BY)F1 recipients.  5  and 6  d  after cell  transfer 0.5 ml of either anti-FV 
antiserum  or normal  mouse serum was administered  i.v.; on the  7th d  spleens  were 
harvested.  Spleens  from mice which  had  received  immune  serum  showed  low  per- 
centages of cells which were positive for virus-specific membrane immunofluorescence 14  IDENTIFICATION OF  Rfv-3 
TABLr  II 
Correlation of Viremia, FV-Induced Cell-Surface Antigen Expression, and Anti-FV Antibody in 
(BIO.A × A)F1 × A Backcross Mice 36 D After FV Inoculation (1,500 FFU) 
Viremia*  FV antigen:l: 
Anti-FV  Low  I Hi7~h 
Antigen:~[Low  .  23  4  ]Antibody_,§ Low  6  .  16 
Viremia* 
Anti-FV 
antibody§ 
[High  L~l  7  High6 
J, Low  5  22 
*  Based on the analysis of the A and (B 10.A ×  A)FI parents of this backcross, high F-MuLV viremia was 
defined as >10  a PFU/ml plasma (8). Values shown are the number of mice in each category. 
:~ FV-induced cell-surface antigens were detected  by direct  membrane immunofluorescence using fluores- 
cein-conjugated goat anti-MLV serum. High was defined as >50% of cells positive. 
§ High antibody was defined as a titer ~4 in the antibody plus complement cytotoxicity assay using AA4 l 
leukemia cells as targets. One mouse was not tested for anti-FV antibody. 
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FIG. 2.  Comparison of virus-specific membrane immunofluorescence of (B 10.A X A)FI spleen cells 
and circulating cytotoxic anti-FV antibody from mice at various times after inoculation. The cells 
were reacted with fluorescein-conjugated  goat anti-MLV serum. The F] serum was tested for anti- 
FV cytotoxic activity using the AA41 tumor cell line as a target  in the antibody plus complement 
cytotoxicity assay. Points are averages from several mice :t: SEM. 
(30-32%), whereas spleens from mice which had received normal mouse serum or no 
serum at all, had  high percentages of positive cells  (57-69%)  (Table III). All spleens 
examined had high levels of virus-specific cytoplasmic immunofluorescence (60-74%), 
indicating that the immune serum had not specifically eliminated virus-infected cells. 
These  results strongly suggest  that  immune  serum  induces virus-specific cell-surface 
antigen loss in vivo. 
FVAntigen Loss on A.BYLeukemi¢ Cells.  A.BY leukemic spleen cells do not normally 
lose FV antigens during the course of FV leukemia  (Table I, Fig.  1).  We wanted to 
know  whether  the  failure  of  A.BY  mice  to  produce  anti-FV  antibody  could  be 
responsible  for  FV-antigen  retention,  or  whether  A.BY  leukemic  spleen  cells  were 
intrinsically resistant  to  modulation of FV  antigens. Therefore,  high  antigen A.BY DON  DOIG  AND  BRUCE  CHESEBRO  15 
TABLE  III 
Loss of FV-Induced Cell-Membrane Antigens after Passive Transfer of lmmune 
Serum 
Virus-specific mem-  Virus-specific cyto- 
Mouse no.  Serum received  brane immunofluores-  plasmic immunofluo- 
cence  rescence 
%  % 
1  Anti-FV  32  74 
2  Anti-FV  31  60 
3  Anti-FV  30  64 
4  NMS  68  69 
5  NMS  64  65 
6  NMS  60  63 
7  NMS  69  72 
8  No serum  57  60 
9  No serum  58  70 
2.5  ×  107 viable early (8-9 d) (B10.A ×  A/WySn)FI spleen cells were transferred i.v. 
to  lethally  irradiated  (900  rads)  (B10.A  X  A.BY)Fj  mice.  These cells  were  68% 
positive in the membrane immunofluorescence assay. 0.5 ml of either anti-FV serum 
or normal B10.A mouse serum (NMS)  was administered on days 5 and 6  after cell 
transfer, and on day 7 spleens were harvested. Spleen cells were tested for cell-surface 
and intracellular (cytoplasmic) virus-specific immunofluorescence. 
TABLE  IV 
FV-Induced Cell-Surface Antigen Loss on Early  (8-9 D) A.BY Leukemic 
Spleen Cells Transferred to Lethally Irradiated Immune Recipients 
Membrane immunofluorescence* 
Experiment  900-rads immune  900-rads nonim- 
Donor  mune 
recipient  recipient 
%  %  % 
66  11, 18  67, 60 
65  11, 23  51, 70 
* 8-9  d  (early)  A.BY  leukemic  spleen  cells  were  transferred  into  lethally 
irradiated  (900  rads)  (B10.A  X  A.BY)FI  hybrids  which  were  previously 
immunized against  FV-induced  cell-surface  antigens or  into  nonimmune 
lethally irradiated recipients. Recipient spleen ceils were examined for viral 
antigens  by  immunofluorescence 7  d  after  cell  transfer.  Percent  of cells 
showing direct  membrane immune fluorescence with  fluoresceinated goat 
anti-Moloney LV serum is shown. 
spleen  cells  were  exposed  to  anti-FV  antibody  by  transfer  to  lethally  irradiated 
hyperimmune (B 10.A  ×  A.BY)Fa recipients. It was observed that early A.BY leukemic 
spleen cells lost FV-specific cell-surface antigens 6 d after transfer (Table IV). Because 
these cells were capable of FV antigen loss, this data suggested that lack of production 
of anti-FV leukemia cell antibody was responsible for the high FV cell-surface antigen 
levels seen in A.BY mice in late stages of leukemia. 
Discussion 
The present results indicate that A.BY and A mice differ from (B10.A  X  A.BY)F1 
and (B 10.A  ×  A)F1 mice in recovery from FV viremia, loss of FV-induced cell-surface 16  IDENTIFICATION OF  Rfv-3 
antigens, and production of cytotoxic anti-FV leukemia cell antibodies. Furthermore, 
in  (B10.A  ×  A)F1  ×  A  backcross  mice,  these  three  parameters  appeared  to  be 
controlled by the same segregating genetic locus, Rfv-3. Thus, in the F1 and backcross 
mice the Rfv-3  r/8 genotype was associated with recovery from viremia, loss of FV cell- 
surface antigens, and anti-FV leukemia cell antibody production. Conversely, in the 
A, A.BY and backcross mice the Rfv-38/~ genotype was associated with lack of recovery 
from viremia, retention of FV antigen, and failure to generate antibodies. It seemed 
likely that these three phenomena were linked by a common mechanism. A number 
of lines of evidence suggested  that  anti-FV  antibody might  be responsible for the 
observed antigen loss and clearance of FV viremia. (a) Loss Of FV-induced cell-surface 
antigen coincided with the appearance of cytotoxic anti-FV antibody in the plasma 
of leukemic mice.  (b)  High antigen early (8-9 d)  Fx  (9)  and A.BY leukemic spleen 
cells  could  be  induced  to  lose  FV  antigen  upon  transfer  to  lethally  irradiated 
hyperimmune mice which had demonstrable cytotoxic anti-FV plasma antibody. (c) 
Adoptive  transfer  of early  (B10.A  ×  A)F1  (high  antigen)  spleen  cells  to  lethally 
irradiated recipients, followed by passive transfer of anti-FV immune serum, provided 
direct evidence that anti-FV antiserum was capable of inducing FV-antigen loss from 
leukemic spleen cell surfaces. It appeared that antibody was acting to modulate FV- 
induced cell-surface antigens (14-18) and was not simply killing virus-infected cells, 
because  the spleen cells retained  intracellular virus-specific antigens.  Furthermore, 
because immune serum was transferred 1 and 2 d before spleen cells were examined, 
it would appear highly unlikely that a population of low FV cell-surface antigen cells 
could have overgrown the spleen in that time. 
If the  mechanism  of Rfv-3r/~-associated antigen  loss  operates  via  control  of the 
production of anti-FV antibodies, then one would expect that if high antigen leukemic 
spleen cells from A  or A.BY mice  (Rfv-3  ~/') were introduced into an environment 
with anti-FV antibodies, they would lose FV cell-surface antigens. This was observed 
upon the transfer of high antigen A.BY spleen cells to lethally irradiated hyperimmune 
recipients. These results suggested that  the failure of A.BY leukemic spleen cells to 
lose FV  antigen  during  the  normal  disease course was  not  a  result of an  intrinsic 
inability of A.BY cells to lose (or modulate) antigen. It seemed likely that FV antigen 
was  not  lost  after  30  d  postinoculation  because  A.BY  mice  were  not  capable  of 
generating anti-FV leukemia cell antibodies.  2 
Interestingly, although the A.BY and A mice usually do not produce cytotoxic anti- 
FV  leukemia  cell  antibodies  late  in  the  disease,  they  do  develop  significant  FV- 
neutralizing antibody titers (B. Chesebro. Manuscript in preparation). It may be that 
clearance of virus  from plasma  by neutralizing antibody is  not  sufficient to effect 
recovery from  viremia.  Apparently,  anti-leukemia  cell  antibodies  are  required  to 
decrease virus production. Because cell-surface FV gp70 may be essential for recog- 
nition of viral cores before virus budding, antibody-mediated modulation or dispersion 
of cell-surface viral proteins could interfere with virus budding and release (19). This 
possibility was supported by our observation of a substantial decrease in the number 
of F-MuLV producing cells (scored as infectious centers) in late leukemic (B10.A  × 
2 Preliminary experiments using an indirect membrane fluorescence assay indicated that late leukemic 
A and A.BY mice had no noncytotoxic leukemia cell binding antibodies in their sera (data not shown). DON  DOIG  AND  BRUCE  CHESEBRO  17 
A)F1  spleens  (B.  Chesebro,  K.  Wehrly,  D.  Doig,  and  J.  Nishio.  Manuscript  in 
preparation). 
Although we think it most likely that Rfv-3 acts as an immunoregulatory gene (20), 
that  influences production of cytotoxic anti-FV  antibodies, other possibilities exist. 
Rfv-3  r/~ could act  to increase interferon production  (21,  22), which would decrease 
virus  production,  and  in  turn,  FV-antigen  expression.  Alternately,  Rfv-3  r/s  could 
increase production of SFFV defective interfering particles, which could contribute to 
recovery  from  F-MuLV  viremia  (23).  Kumar  et  al.  (24)  have  demonstrated  the 
existence of a gene (FV-3) which confers resistance to nonspecific immunosuppression 
induced by FV.  Rfv-3 may similarly regulate susceptibility to immunosuppression 
(25) but is not likely to be identical to FV-3 because Rfv-3  r is dominant for antibody 
production, and FV-3" is dominant for susceptibility to immunosuppression. 
Several mouse genes were recently shown to influence MLV viremia and leukemia 
(26). Because FV and MLV are immunologically cross-reactive, it would seem likely 
that  any mouse  genes which  influence immunological  recognition of FV  or MLV 
antigens might be of importance to both systems. However, at present it appears that 
Rfv-3 has no influence on MLV viremia as B10 and A.BY mice, which differ at Rfv- 
3, have similar responses to MLV (26). 
Wheelock et al.  (27)  have suggested that statolon-induced anti-FV antibody may 
induce both regression of FV splenomegaly and antigenic modulation of FV antigens 
which could lead to the persistence of leukemia cells.  Our results confirmed that FV 
leukemia cells could persist in the presence ofcytotoxic antibody, and FV cell-surface 
antigens were quantitatively decreased on these leukemia cells (9). However, antibody 
alone appeared unable to induce regression of massive splenomegaly. Furthermore, 
our preliminary experiments indicate that  low antigen late leukemic Fx spleen cells 
grow in hyperimmune recipient mice (data to be published). It seems likely that other 
mechanisms such as cell-mediated cytotoxicity (CMC) may be necessary for recovery 
from  splenomegaly  (28).  It  remains  unclear  whether  modulation  of cell-surface 
antigens  has  any bearing on  growth  of tumor cells in  the  face of a  tumor-specific 
immune response. Antibody-induced antigenic modulation may interfere with CMC 
or other host defense mechanisms essential for elimination of tumor. If so, the kinetics 
of the  CMC  response  compared  with  the  antibody  response  would  be  of critical 
importance to whether or not recovery from leukemia ultimately occurs. 
Summary 
A  single  genetic locus,  Rfv-3, influenced Friend virus  (FV)  viremia,  loss  of FV- 
induced cell-surface antigens from leukemia cells, and generation of anti-FV antibod- 
ies. 30-90 d after FV infection leukemic spleen cells from (B10.A X  A)F1 and (B10.A 
X  A.BY)F1 mice (Rfv-3  r/s) were found to have low FV-induced cell-surface antigen 
expression compared to leukemic spleen cells from A  and A.BY mice (Rfv-3S/~). In 
addition,  these  F1  mice  recovered  from  viremia  and  generated  cytotoxic anti-FV 
antibodies.  A  and  A.BY mice did  not  recover from viremia and  failed to generate 
anti-FV antibodies. Anti-FV leukemia cell antibody appeared to mediate FV-antigen 
loss because decrease of FV cell-surface antigens occurred at the same time as anti-FV 
antibody appeared in the plasma of F1 mice, and passive transfer of anti-FV antisera 
induced modulation of FV cell-surface antigens. Rfv-3 did not influence an intrinsic 18  IDENTIFICATION OF  Rfv-3 
ability of FV  antigens  to  be  modulated  from  Rfv-3  s/s  leukemia  cells because  FV 
antigen  loss from  Rfv-38/~ spleen cells occurred after transfer of cells to an  immune 
environment. 
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